Skip to main content

Articles

Page 3 of 34

  1. Alzheimer’s disease (AD) is the sixth leading cause of death in the USA. It is established that neuroinflammation contributes to the synaptic loss, neuronal death, and symptomatic decline of AD patients. Accum...

    Authors: Kylene P. Daily, Asmaa Badr, Mostafa Eltobgy, Shady Estfanous, Owen Whitham, Michelle H. Tan, Cierra Carafice, Kathrin Krause, Andrew McNamara, Kaitlin Hamilton, Samuel Houle, Spandan Gupta, Gauruv A. Gupta, Shruthi Madhu, Julie Fitzgerald, Abbey A. Saadey…
    Citation: Alzheimer's Research & Therapy 2024 16:29
  2. Cardiometabolic multimorbidity is associated with an increased risk of dementia, but the pathogenic mechanisms linking them remain largely undefined. We aimed to assess the associations of cardiometabolic mult...

    Authors: Qiong-Yao Li, He-Ying Hu, Gao-Wen Zhang, Hao Hu, Ya-Nan Ou, Liang-Yu Huang, An-Yi Wang, Pei-Yang Gao, Li-Yun Ma, Lan Tan and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2024 16:28
  3. Mild cognitive impairment (MCI) is a neurocognitive disorder in which the cognitive and mental abilities of humans are declined. Transcranial direct-current stimulation (tDCS) is an emerging noninvasive brain ...

    Authors: Soheila Rezakhani, Mahmood Amiri, Atefe Hassani, Khadijeh Esmaeilpour and Vahid Sheibani
    Citation: Alzheimer's Research & Therapy 2024 16:27
  4. Advancement in screening tools accessible to the general population for the early detection of Alzheimer’s disease (AD) and prediction of its progression is essential for achieving timely therapeutic intervent...

    Authors: Fernando García-Gutiérrez, Montserrat Alegret, Marta Marquié, Nathalia Muñoz, Gemma Ortega, Amanda Cano, Itziar De Rojas, Pablo García-González, Clàudia Olivé, Raquel Puerta, Ainhoa García-Sanchez, María Capdevila-Bayo, Laura Montrreal, Vanesa Pytel, Maitee Rosende-Roca, Carla Zaldua…
    Citation: Alzheimer's Research & Therapy 2024 16:26
  5. Secondary prevention clinical trials for Alzheimer’s disease (AD) target amyloid accumulation in asymptomatic, amyloid-positive individuals, but it is unclear to what extent other pathophysiological processes,...

    Authors: Clarissa D. Morales, Dejania Cotton-Samuel, Patrick J. Lao, Julia F. Chang, Jeffrey D. Pyne, Mohamad J. Alshikho, Rafael V. Lippert, Kelsang Bista, Christiane Hale, Natalie C. Edwards, Kay C. Igwe, Kacie Deters, Molly E. Zimmerman and Adam M. Brickman
    Citation: Alzheimer's Research & Therapy 2024 16:25
  6. Cholesterol is an essential component of the neuronal cell membrane and is crucial for neuronal function; however, the role of cholesterol levels in Parkinson’s disease (PD) is debatable. This study investigat...

    Authors: Seong Ho Jeong, Seok Jong Chung, Han Soo Yoo, Jin Ho Jung, Jong Sam Baik, Young H. Sohn and Phil Hyu Lee
    Citation: Alzheimer's Research & Therapy 2024 16:24
  7. Combining multimodal lifestyle interventions and disease-modifying drugs (novel or repurposed) could provide novel precision approaches to prevent cognitive impairment. Metformin is a promising candidate in vi...

    Authors: Mariagnese Barbera, Jenni Lehtisalo, Dinithi Perera, Malin Aspö, Mary Cross, Celeste A. De Jager Loots, Emanuela Falaschetti, Naomi Friel, José A. Luchsinger, Hanna Malmberg Gavelin, Markku Peltonen, Geraint Price, Anna Stigsdotter Neely, Charlotta Thunborg, Jaakko Tuomilehto, Francesca Mangialasche…
    Citation: Alzheimer's Research & Therapy 2024 16:23
  8. Alzheimer’s disease (AD) is one of the most burdening diseases of the century with no disease-modifying treatment at this time. Nonhuman primates (NHPs) share genetic, anatomical, and physiological similaritie...

    Authors: Zhouquan Jiang, Jing Wang, Yongpeng Qin, Shanggong Liu, Bin Luo, Fan Bai, Huiyi Wei, Shaojuan Zhang, Junjie Wei, Guoyu Ding, Long Ma, Shu He, Rongjie Chen, Ying Sun, Yi Chen, Lu Wang…
    Citation: Alzheimer's Research & Therapy 2024 16:22
  9. Mild behavioral impairment (MBI) has been commonly reported in early Alzheimer’s disease (AD) but rarely using biomarker-defined samples. It is also unclear whether genetic polymorphisms influence MBI in such ...

    Authors: Veronika Matuskova, Katerina Veverova, Dylan J. Jester, Vaclav Matoska, Zahinoor Ismail, Katerina Sheardova, Hana Horakova, Jiri Cerman, Jan Laczó, Ross Andel, Jakub Hort and Martin Vyhnalek
    Citation: Alzheimer's Research & Therapy 2024 16:21
  10. Effective, disease-modifying therapeutics for the treatment of Alzheimer’s disease (AD) remain a large unmet need. Extensive evidence suggests that amyloid beta (Aβ) is central to AD pathophysiology, and Aβ ol...

    Authors: Christopher H. van Dyck, Adam P. Mecca, Ryan S. O’Dell, Hugh H. Bartlett, Nina G. Diepenbrock, Yiyun Huang, Mary E. Hamby, Michael Grundman, Susan M. Catalano, Anthony O. Caggiano and Richard E. Carson
    Citation: Alzheimer's Research & Therapy 2024 16:20
  11. Epileptic seizures are an established comorbidity of Alzheimer’s disease (AD). Subclinical epileptiform activity (SEA) as detected by 24-h electroencephalography (EEG) or magneto-encephalography (MEG) has been...

    Authors: Amber Nous, Laura Seynaeve, Odile Feys, Vincent Wens, Xavier De Tiège, Pieter Van Mierlo, Amir G. Baroumand, Koenraad Nieboer, Gert-Jan Allemeersch, Shana Mangelschots, Veronique Michiels, Julie van der Zee, Christine Van Broeckhoven, Annemie Ribbens, Ruben Houbrechts, Sara De Witte…
    Citation: Alzheimer's Research & Therapy 2024 16:19
  12. Authors: Francheska Delgado‑Peraza, Carlos Nogueras‑Ortiz, Anja Hviid Simonsen, De’Larrian DeAnté Knight, Pamela J. Yao, Edward J. Goetzl, Camilla Steen Jensen, Peter Høgh, Hanne Gottrup, Karsten Vestergaard, Steen Gregers Hasselbalch and Dimitrios Kapogiannis
    Citation: Alzheimer's Research & Therapy 2024 16:18

    The original article was published in Alzheimer's Research & Therapy 2023 15:156

  13. Plant-based diets may provide protection against cognitive decline and Alzheimer’s disease, but observational data have not been consistent. Previous studies include early life confounding from socioeconomic c...

    Authors: Claire T. McEvoy, Amy Jennings, Claire J. Steves, Alexander Macgregor, Tim Spector and Aedin Cassidy
    Citation: Alzheimer's Research & Therapy 2024 16:17
  14. Blood-based biomarkers for dementia are gaining attention due to their non-invasive nature and feasibility in regular healthcare settings. Here, we explored the associations between 249 metabolites with all-ca...

    Authors: Yi-Xuan Qiang, Jia You, Xiao-Yu He, Yu Guo, Yue-Ting Deng, Pei-Yang Gao, Xin-Rui Wu, Jian-Feng Feng, Wei Cheng and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2024 16:16
  15. Alzheimer’s disease (AD) is a degenerative neurological disorder. Recent studies have indicated that histone deacetylases (HDACs) are among the most prominent epigenetic therapy targets and that HDAC inhibitor...

    Authors: Miaomiao Zhang, Wanyao Wang, Qun Ye, Yun Fu, Xuemin Li, Ke Yang, Fan Gao, An Zhou, Yonghui Wei, Shuang Tian, Shen Li, Fengjiang Wei, Wentao Shi and Wei-Dong Li
    Citation: Alzheimer's Research & Therapy 2024 16:15
  16. Uncovering the functional relevance underlying verbal declarative memory (VDM) genome-wide association study (GWAS) results may facilitate the development of interventions to reduce age-related memory decline ...

    Authors: Hao Mei, Jeannette Simino, Lianna Li, Fan Jiang, Joshua C. Bis, Gail Davies, W David Hill, Charley Xia, Vilmundur Gudnason, Qiong Yang, Jari Lahti, Jennifer A. Smith, Mirna Kirin, Philip De Jager, Nicola J. Armstrong, Mohsen Ghanbari…
    Citation: Alzheimer's Research & Therapy 2024 16:14
  17. Amyloid-β42 (Aβ42) aggregation consists of a complex chain of nucleation events producing soluble oligomeric intermediates, which are considered the major neurotoxic agents in Alzheimer’s disease (AD). Cerebral l...

    Authors: Alessandra Bigi, Liliana Napolitano, Devkee M. Vadukul, Fabrizio Chiti, Cristina Cecchi, Francesco A. Aprile and Roberta Cascella
    Citation: Alzheimer's Research & Therapy 2024 16:13
  18. Cerebrospinal fluid (CSF) complement activation is a key part of neuroinflammation that occurs in the early stages of Alzheimer’s disease (AD). However, the associations of CSF complement proteins with AD path...

    Authors: Meng Li, Ya-Hui Ma, Yun Guo, Jia-Yao Liu and Lan Tan
    Citation: Alzheimer's Research & Therapy 2024 16:12
  19. Authors: Long Xie, Sandhitsu R. Das, Laura E. M. Wisse, Ranjit Ittyerah, Robin de Flores, Leslie M. Shaw, Paul A. Yushkevich and David A. Wolk
    Citation: Alzheimer's Research & Therapy 2024 16:11

    The original article was published in Alzheimer's Research & Therapy 2023 15:79

  20. The Genetic Frontotemporal Initiative Staging Group has proposed clinical criteria for the diagnosis of prodromal frontotemporal dementia (FTD), termed mild cognitive and/or behavioral and/or motor impairment ...

    Authors: Alberto Benussi, Enrico Premi, Mario Grassi, Antonella Alberici, Valentina Cantoni, Stefano Gazzina, Silvana Archetti, Roberto Gasparotti, Giorgio G. Fumagalli, Arabella Bouzigues, Lucy L. Russell, Kiran Samra, David M. Cash, Martina Bocchetta, Emily G. Todd, Rhian S. Convery…
    Citation: Alzheimer's Research & Therapy 2024 16:10
  21. Metabotropic glutamate receptor 5 (mGluR5) is involved in regulating integrative brain function and synaptic transmission. Aberrant mGluR5 signaling and relevant synaptic failure play a key role in the initial...

    Authors: Jie Wang, Yingfang He, Xing Chen, Lin Huang, Junpeng Li, Zhiwen You, Qi Huang, Shuhua Ren, Kun He, Roger Schibli, Linjing Mu, Yihui Guan, Qihao Guo, Jun Zhao and Fang Xie
    Citation: Alzheimer's Research & Therapy 2024 16:9
  22. Specific peripheral proteins have been implicated to play an important role in the development of Alzheimer’s disease (AD). However, the roles of additional novel protein biomarkers in AD etiology remains elus...

    Authors: Jingjing Zhu, Shuai Liu, Keenan A. Walker, Hua Zhong, Dalia H. Ghoneim, Zichen Zhang, Praveen Surendran, Sarah Fahle, Adam Butterworth, Md Ashad Alam, Hong-Wen Deng, Chong Wu and Lang Wu
    Citation: Alzheimer's Research & Therapy 2024 16:8
  23. APOE4 is the strongest genetic risk factor for sporadic Alzheimer’s disease (AD), whereas APOE2 confers protection. However, effects of APOE on neurodegeneration in cognitively intact individuals, and how these a...

    Authors: Emilie T. Reas, Curtis Triebswetter, Sarah J. Banks and Linda K. McEvoy
    Citation: Alzheimer's Research & Therapy 2024 16:7
  24. Repeated sessions of training and non-invasive brain stimulation have the potential to enhance cognition in patients with cognitive impairment. We hypothesized that combining cognitive training with anodal tra...

    Authors: Daria Antonenko, Anna Elisabeth Fromm, Friederike Thams, Anna Kuzmina, Malte Backhaus, Elena Knochenhauer, Shu-Chen Li, Ulrike Grittner and Agnes Flöel
    Citation: Alzheimer's Research & Therapy 2024 16:6
  25. Alzheimer’s dementia (AD) pathogenesis involves complex mechanisms, including microRNA (miRNA) dysregulation. Integrative network and machine learning analysis of miRNA can provide insights into AD pathology a...

    Authors: Sang-Won Han, Jung-Min Pyun, Paula J. Bice, David A. Bennett, Andrew J. Saykin, Sang Yun Kim, Young Ho Park and Kwangsik Nho
    Citation: Alzheimer's Research & Therapy 2024 16:5
  26. Amyloid beta (Aβ) deposits and hyperphosphorylated tau (p-tau) accumulation have been identified in the retina of Alzheimer’s disease (AD) patients and transgenic AD mice. Previous studies have shown that reti...

    Authors: Cristina Nuñez-Diaz, Emelie Andersson, Nina Schultz, Dovilė Pocevičiūtė, Oskar Hansson, K Peter R. Nilsson and Malin Wennström
    Citation: Alzheimer's Research & Therapy 2024 16:4
  27. Recently, single-nucleus RNA-seq (snRNA-seq) analyses have revealed important cellular and functional features of Alzheimer's disease (AD), a prevalent neurodegenerative disease. However, our knowledge regardi...

    Authors: Andi Liu, Brisa S. Fernandes, Citu Citu and Zhongming Zhao
    Citation: Alzheimer's Research & Therapy 2024 16:3
  28. Disease-modifying treatments for Alzheimer’s disease highlight the need for early detection of cognitive decline. However, at present, most primary care providers do not perform routine cognitive testing, in p...

    Authors: Ali Jannati, Claudio Toro-Serey, Joyce Gomes-Osman, Russell Banks, Marissa Ciesla, John Showalter, David Bates, Sean Tobyne and Alvaro Pascual-Leone
    Citation: Alzheimer's Research & Therapy 2024 16:2
  29. Apolipoprotein-E (APOE) genetic testing for Alzheimer’s disease is becoming more important as clinical trials are increasingly targeting individuals carrying APOE-ε4 alleles. Little is known about the interest...

    Authors: Lisa Waterink, Larissa A. Masselink, Sven J. van der Lee, Leonie N. C. Visser, Solange Cleutjens, Jetske van der Schaar, Argonde C. van Harten, Philip Scheltens, Sietske A. M. Sikkes, Wiesje M. van der Flier and Marissa D. Zwan
    Citation: Alzheimer's Research & Therapy 2024 16:1
  30. Disturbances in brain cholesterol homeostasis may be involved in the pathogenesis of Alzheimer’s disease (AD). Lipid-lowering medications could interfere with neurodegenerative processes in AD through choleste...

    Authors: Bojana Petek, Henrike Häbel, Hong Xu, Marta Villa-Lopez, Irena Kalar, Minh Tuan Hoang, Silvia Maioli, Joana B. Pereira, Shayan Mostafaei, Bengt Winblad, Milica Gregoric Kramberger, Maria Eriksdotter and Sara Garcia-Ptacek
    Citation: Alzheimer's Research & Therapy 2023 15:220
  31. Modifiable lifestyle behaviors account for a large proportion of dementia risk. However, the combined contributions of multidomain lifestyle patterns to cognitive aging are poorly understood, as most studies h...

    Authors: Emily W. Paolillo, Rowan Saloner, Anna VandeBunte, Shannon Lee, David A. Bennett and Kaitlin B. Casaletto
    Citation: Alzheimer's Research & Therapy 2023 15:221
  32. Clinical variants of primary progressive aphasia (PPA) are diagnosed based on characteristic patterns of language deficits, supported by corresponding neural changes on brain imaging. However, there is (i) con...

    Authors: Siddharth Ramanan, Ajay D. Halai, Lorna Garcia-Penton, Alistair G. Perry, Nikil Patel, Katie A. Peterson, Ruth U. Ingram, Ian Storey, Stefano F. Cappa, Eleonora Catricala, Karalyn Patterson, James B. Rowe, Peter Garrard and Matthew A. Lambon Ralph
    Citation: Alzheimer's Research & Therapy 2023 15:219
  33. White matter (WM) microstructural changes in the hippocampal cingulum bundle (CBH) in Alzheimer’s disease (AD) have been described in cohorts of largely European ancestry but are lacking in other populations.

    Authors: Lauren R. Hirschfeld, Rachael Deardorff, Evgeny J. Chumin, Yu-Chien Wu, Brenna C. McDonald, Sha Cao, Shannon L. Risacher, Dahyun Yi, Min Soo Byun, Jun-Young Lee, Yu Kyeong Kim, Koung Mi Kang, Chul-Ho Sohn, Kwangsik Nho, Andrew J. Saykin and Dong Young Lee
    Citation: Alzheimer's Research & Therapy 2023 15:218
  34. Neurodegeneration and structural changes in the brain due to amyloid deposition have been observed even in individuals with mild cognitive impairment (MCI). EEG measurement is considered an effective tool beca...

    Authors: Osamu Katayama, Yaakov Stern, Christian Habeck, Sangyoon Lee, Kenji Harada, Keitaro Makino, Kouki Tomida, Masanori Morikawa, Ryo Yamaguchi, Chiharu Nishijima, Yuka Misu, Kazuya Fujii, Takayuki Kodama and Hiroyuki Shimada
    Citation: Alzheimer's Research & Therapy 2023 15:217
  35. Alzheimer’s disease (AD) is characterized by cognitive dysfunction and amyloid plaques composed of the amyloid-beta peptide (Aβ). APOE is the greatest genetic risk for AD with APOE4 increasing risk up to ~ 15-fol...

    Authors: Ana C. Valencia-Olvera, Deebika Balu, Shreya Bellur, Thomas McNally, Yaseen Saleh, Don Pham, Shivesh Ghura, Jason York, Jan O. Johansson, Mary Jo LaDu and Leon Tai
    Citation: Alzheimer's Research & Therapy 2023 15:216
  36. NeuroEPO plus is a recombinant human erythropoietin without erythropoietic activity and shorter plasma half-life due to its low sialic acid content. NeuroEPO plus prevents oxidative damage, neuroinflammation, ...

    Authors: Saily Sosa, Giosmany Bringas, Nelky Urrutia, Ana Ivis Peñalver, Danay López, Evelio González, Ana Fernández, Zenaida Milagros Hernández, Ariel Viña, Yamile Peña, Juan Felipe Batista, Carmen Valenzuela, Kalet León, Tania Crombet, Teresita Rodríguez and Leslie Pérez
    Citation: Alzheimer's Research & Therapy 2023 15:215
  37. Alzheimer’s disease (AD) and vascular dementia (VaD) are two of the commonest causes of dementia in the elderly. Of the myriad biomolecules implicated in dementia pathogenesis, sphingolipids have attracted rel...

    Authors: Xin Ying Chua, Federico Torta, Joyce R. Chong, Narayanaswamy Venketasubramanian, Saima Hilal, Markus R. Wenk, Christopher P. Chen, Thiruma V. Arumugam, Deron R. Herr and Mitchell K. P. Lai
    Citation: Alzheimer's Research & Therapy 2023 15:214
  38. Genome-wide association studies demonstrate that Alzheimer’s disease (AD) has a highly polygenic architecture, where thousands of independent genetic variants explain risk with high classification accuracy. Th...

    Authors: Thomas Lancaster, Byron Creese, Valentina Escott-Price, Ian Driver, Georgina Menzies, Zunera Khan, Anne Corbett, Clive Ballard, Julie Williams, Kevin Murphy and Hannah Chandler
    Citation: Alzheimer's Research & Therapy 2023 15:213
  39. Developing a screening method for identifying individuals at higher risk of elevated brain amyloid burden is important to reduce costs and burden to patients in clinical trials on Alzheimer’s disease or the cl...

    Authors: Noriyuki Kimura, Tomoki Aota, Yasuhiro Aso, Kenichi Yabuuchi, Kotaro Sasaki, Teruaki Masuda, Atsuko Eguchi, Yoshitaka Maeda, Ken Aoshima and Etsuro Matsubara
    Citation: Alzheimer's Research & Therapy 2023 15:212
  40. Identifying individuals with mild cognitive impairment (MCI) who are likely to progress to Alzheimer’s disease and related dementia disorders (ADRD) would facilitate the development of individualized preventio...

    Authors: Gang Li, Nicola Toschi, Viswanath Devanarayan, Richard Batrla, Tommaso Boccato, Min Cho, Matteo Ferrante, Feride Frech, James E. Galvin, David Henley, Soeren Mattke, Susan De Santi and Harald Hampel
    Citation: Alzheimer's Research & Therapy 2023 15:211
  41. Dementia is defined as a cognitive decline that affects functional status. Longitudinal ageing surveys often lack a clinical diagnosis of dementia though measure cognition and daily function over time. We used...

    Authors: Amin Gharbi-Meliani, François Husson, Henri Vandendriessche, Eleonore Bayen, Kristine Yaffe, Anne-Catherine Bachoud-Lévi and Laurent Cleret de Langavant
    Citation: Alzheimer's Research & Therapy 2023 15:209
  42. To estimate the perceived value of additional testing with amyloid-PET in Euros in healthy participants acting as analogue patients with mild cognitive impairment (MCI).

    Authors: I. S. van Maurik, E. D. Bakker, A. A. J. M. van Unnik, H. M. Broulikova, M. D. Zwan, E. van de Giessen, J. Berkhof, F. H. Bouwman, J. E. Bosmans and W. M. van der Flier
    Citation: Alzheimer's Research & Therapy 2023 15:208
  43. Previous studies demonstrated increases in diagnostic confidence and change in patient management after amyloid-PET. However, studies investigating longitudinal outcomes over an extended period of time are lim...

    Authors: Lyduine E. Collij, Gill Farrar, Marissa Zwan, Elsmarieke van de Giessen, Rik Ossenkoppele, Frederik Barkhof, Annemieke J. M. Rozemuller, Yolande A. L. Pijnenburg, Wiesje M. van der Flier and Femke Bouwman
    Citation: Alzheimer's Research & Therapy 2023 15:207
  44. High gait variability is associated with neurodegeneration and cognitive impairments and is predictive of cognitive impairment and dementia. The objective of this study was to identify cortical or subcortical ...

    Authors: Seonjeong Byun, Hyang Jun Lee, Jun Sung Kim, Euna Choi, Subin Lee, Tae Hui Kim, Jae Hyoung Kim, Ji Won Han and Ki Woong Kim
    Citation: Alzheimer's Research & Therapy 2023 15:206
  45. Cognitive complaints are often regarded as an early sign of Alzheimer’s disease (AD) but may also occur in several other conditions and contexts. This study examines the correlates of cognitive complaint traje...

    Authors: Federica Cacciamani, Ariane Bercu, Vincent Bouteloup, Leslie Grasset, Vincent Planche, Geneviève Chêne and Carole Dufouil
    Citation: Alzheimer's Research & Therapy 2023 15:205
  46. There are increasing reports on the cognitive and emotional benefits of positive reminiscence therapy in older people. The objective of this study is to assess the differential improvement of the quality of li...

    Authors: Alba Villasán Rueda, Antonio Sánchez Cabaco, Manuel Alejandro Mejía-Ramírez, Rosa Marina Afonso and Eduardo Castillo-Riedel
    Citation: Alzheimer's Research & Therapy 2023 15:204
  47. Participant retention is a key factor that affects clinical trial integrity. Trial protocols estimate attrition as a function of sample size calculations. Alzheimer’s disease (AD) is an area of active treatmen...

    Authors: Marina Ritchie, Daniel L. Gillen and Joshua D. Grill
    Citation: Alzheimer's Research & Therapy 2023 15:203
  48. Identification of patients with idiopathic normal pressure hydrocephalus (iNPH) in a collective with suspected neurodegenerative disease is essential. This study aimed to determine the metabolic spatial covari...

    Authors: Alexander Rau, Nils Schröter, Ganna Blazhenets, Christoph Maurer, Horst Urbach, Philipp T. Meyer and Lars Frings
    Citation: Alzheimer's Research & Therapy 2023 15:202